Microtube Array Membrane (MTAM)-Based Encapsulated Cell Therapy for Cancer Treatment

Area of Science:

• Biomedical Engineering
• Cancer Immunotherapy
• Materials Science

Background:

• Cancer treatment increasingly focuses on immunotherapy, with Encapsulated Cell Therapy (ECT) offering targeted delivery of therapeutic molecules.
• Traditional ECT systems face limitations: macro-scale vehicles have poor diffusion, while micro-scale ones lack retrievability, posing biosafety concerns.
• A 'middle-ground' approach is needed to balance diffusion, surface area, and patient safety in ECT.

Purpose of the Study:

• To adapt electrospun Polysulfone (PSF) Microtube Array Membranes (MTAMs) as a novel, retrievable vehicle for Encapsulated Cell Therapy (ECT).
• To evaluate the efficacy of hybridoma cells encapsulated in PSF MTAMs for producing CEACAM6 antibodies to suppress specific cancer cell lines.
• To assess the viability of encapsulated cells and antibody production over time, both in vitro and in vivo.

Main Methods:

• Development and utilization of patented electrospun Polysulfone (PSF) Microtube Array Membranes (MTAMs).
• Encapsulation of hybridoma cells within PSF MTAMs for continuous production of CEACAM6 antibodies.
• In vitro and in vivo testing of the system's efficacy against A549, MDA-MB-468, and PC 3 cancer cell lines over 21 days.

Main Results:

• PSF MTAMs demonstrated excellent diffusion and surface area while remaining retrievable, addressing limitations of traditional ECT vehicles.
• Hybridoma cells encapsulated in PSF MTAMs showed high viability and continuous secretion of CEACAM6 antibodies.
• Significant suppression of MDA-MB-468 cancer cells was observed throughout the 21-day experimental period.

Conclusions:

• PSF MTAMs serve as an effective three-dimensional (3D) cell culture substrate and a promising vehicle for Encapsulated Cell Therapy (ECT).
• The system demonstrated potential for sustained anti-cancer activity through antibody production.
• Further long-term in vivo studies (>6 months) are required before clinical application.